ASX Announcement: Appointment of CEO
January 19, 2023
Control Bionics Ltd (ASX: CBL) is pleased to announce the appointment of Jeremy Steele as Chief Executive Officer and a member of the board, effective from 19 January 2023.
Menu
Control Bionics Ltd (ASX: CBL) is pleased to announce the appointment of Jeremy Steele as Chief Executive Officer and a member of the board, effective from 19 January 2023.
Don’t miss this poster at ASHA: Improving Traditional Eye Gaze Access to Augmentative and Alternative Communication (AAC) Devices. Learn more.
Control Bionics continues to expand our leadership team with new Head of Sales – Australia, Annette Curry. Annette brings years of experience as a nurse practitioner, sales and marketing leader.
Control Bionics is excited to announce the expansion of their management team with Vice President – North America, Todd Tyler.
We’re changing our look, but not our mission to become the world’s leading provider of innovative augmentative communication and control devices for people with speech and movement disabilities.
Control Bionics CEO Rob Wong sat down with the podcast Fear and Greed this week to discuss how Control Bionics helps patients with some of the most debilitating conditions to communicate.
As a regular contributor of Biotech Daily, which provides news on ASX-listed biotechnology companies, Dr. Boreham’s Crucible provides analysis of the biotech sector in Australia. Last week Control Bionics was featured in an article on the site.
Rob Wong, CEO of Control Bionics, chats with Alan Kohler from Eureka Report to discuss the latest news from the newly ASX-listed business. ” …
Medtech company Control Bionics (ASX:CBL) will list on the ASX next week. The company’s EMG (electromyography)-based technology helps people with disabilities inhibiting communications to do so
USA
745 Center Street, Suite 303
Milford OH 45150
AUSTRALIA
697 Burke Road, Level 5, Suite 5.01
Camberwell VIC 3124
CANADA
Bridges Canada
2123 McCowan Road
Scarborough, Ontario M1S 3Y6
JAPAN
©2012-2023 Control Bionics, Inc. All Rights Reserved
